Evidence map›Paper›PMID 27930766›Full record

ArticleJAMA oncology2017

Differences in the Prevalence of Human Papillomavirus (HPV) in Head and Neck Squamous Cell Cancers by Sex, Race, Anatomic Tumor Site, and HPV Detection Method.

Gypsyamber D'Souza, William H Westra, Steven J Wang, Annemieke van Zante, Alicia Wentz, Nicole Kluz, Eleni Rettig, William R Ryan, Patrick K Ha, Hyunseok Kang and 6 more

Open access · greenAbstract read
In one paragraph

Article in JAMA oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 7 pooled it
12.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 7 syntheses or guidelines pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Genomic Enrichment and Functional Impact of TP53 and CYLD Alterations in Recurrent and Metastatic HPV-Associated Head and Neck Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

Gypsyamber D'SouzaDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.
William H WestraDepartment of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Steven J WangDepartment of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California.
Annemieke van ZanteDepartment of Pathology, University of California-San Francisco Medical Center, San Francisco, California.
Alicia WentzDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.
Nicole KluzDepartment of Epidemiology, Johns Hopkins School of Public Health, Baltimore, Maryland.
Eleni RettigDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
William R RyanDepartment of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California.
Patrick K HaDepartment of Otolaryngology-Head and Neck Surgery, University of California-San Francisco, San Francisco, California.
Hyunseok KangDepartment of Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Justin BishopDepartment of Pathology, University of California-San Francisco Medical Center, San Francisco, California.
Harry QuonDepartment of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Ana P KiessDepartment of Radiation Oncology, Johns Hopkins School of Medicine, Baltimore, Maryland.
Jeremy D RichmonDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
David W EiseleDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
Carole FakhryDepartment of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, Maryland.
Johns Hopkins University · USJohns Hopkins Medicine · USUniversity of California, San Francisco · USUniversity of California San Francisco Medical Center · US

Funding

TUMOR SUPPRESOR GENE PROMOTER HYPERMETHYLATION FOR DETECTION OF HEAD AND NECKP50DE019032 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI SIDRANSKY, DAVID · 2007 to 2016
$27.1M
Impacting the oral HPV continuum: prevention, screening, and early detectionR35DE026631 · NIDCR · JOHNS HOPKINS UNIVERSITY · PI D'SOUZA, GYPSYAMBER · 2016 to 2023
$8.4M
NIDCR NIH HHS P50 DE019032NIDCR NIH HHS R35 DE026631
6 · The paper itself

Abstract

importanceHuman papillomavirus (HPV) causes an increasing proportion of oropharyngeal squamous cell carcinomas (OPSCCs), particularly in white men. The prevalence of HPV among other demographic groups and other anatomic sites of HNSCC is unclear.

objectiveTo explore the role of HPV tumor status among women and nonwhites with OPSCC and patients with nonoropharyngeal head and neck squamous cell carcinoma (non-OP HNSCC). DESIGN, SETTING, AND

participantsRetrospective cohort study at 2 tertiary academic centers including cases diagnosed 1995 through 2012, oversampled for minorities and females. A stratified random sample of 863 patients with newly diagnosed SCC of the oral cavity, oropharynx, larynx, or nasopharynx was used. MAIN OUTCOMES AND MEASURES: Outcomes were HPV status as measured by p16 immunohistochemical analysis, HPV16 DNA in situ hybridization (ISH), and high-risk HPV E6/E7 mRNA ISH.

resultsOf 863 patients, 551 (63.9%) were male and median age was 58 years (interquartile range, 51-68 years). Among 240 OPSCCs, 144 (60%) were p16 positive (p16+), 115 (48%) were HPV16 DNA ISH positive (ISH16+), and 134 (56%) were positive for any oncogenic HPV type (ISH+). From 1995 to 2012, the proportion of p16+ OPSCC increased significantly among women (from 29% to 77%; P = .005 for trend) and men (36% to 72%; P < .001 for trend), as well as among whites (39% to 86%; P < .001 for trend) and nonwhites (32% to 62%; P = .02 for trend). Similar results were observed for ISH+ OPSCC (P ≤ .01 for all). Among 623 non-OP HNSCCs, a higher proportion were p16+ compared with ISH positive (62 [10%] vs 30 [5%]; P = .001). A high proportion (26 of 62 [42%]) of these p16+ non-OP HNSCCs were found in sites adjacent to the oropharynx. The proportion of p16+ and ISH+ non-OP HNSCCs were similar by sex. Over time, the proportion of non-OP HNSCCs that were p16+ (or ISH+) increased among whites (P = .04 for trend) but not among nonwhites (each P > .51 for trend). Among OPSCCs, p16 had high sensitivity (100%), specificity (91%), and positive (93%) and negative predictive value (100%) for ISH positivity. In non-OP HNSCCs, p16 had lower sensitivity (83%) and positive predictive value (40%) but high specificity (94%) and negative predictive value (99%) for ISH positivity. CONCLUSIONS AND RELEVANCE: During 1995 through 2012, the proportion of OPSCCs caused by HPV has increased significantly. This increase was not restricted to white men but was a consistent trend for women and men, as well as for white and nonwhite racial groups. Few non-OP HNSCCs were HPV related. P16 positivity was a good surrogate for ISH+ tumor status among OPSCC, but not a good surrogate for non-OP HNSCC.

Identifiers

PMID27930766
PMCPMC7286346
OpenAlexW2560255642

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.